Therapeutic Advances in Medical Oncology最新文献

{"title":"Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status.","authors":"Yue Qiu, Yaqin Shi, Zhujun Chao, Xinyu Zhu, Yan Chen, Linlin Lu","doi":"10.1177/17588359241311379","DOIUrl":"https://doi.org/10.1177/17588359241311379","url":null,"abstract":"<p><p>Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers. In response to this gap, antibody-drug conjugates (ADCs) have emerged as a promising approach. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy, which allows for the targeted delivery of a cytotoxic payload to cancer cells. ADCs have been used as adjuvant chemotherapeutic treatments and salvage therapies across various breast cancer subtypes, which have greatly improved the prognosis of breast cancer patients. Numerous ongoing clinical trials seek to optimize dosing strategies and identify patient populations that would benefit most from ADCs. This review presents an updated and comprehensive overview of emerging investigational ADCs for treating breast cancer patients with various HER2 subtypes. These ADCs are spearheading a new era in targeted cancer therapy, promising to innovate treatment paradigms for both HER2-positive and HER2-low breast cancers.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241311379"},"PeriodicalIF":4.3,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy.","authors":"Davide Izzo, Liliana Ascione, Lorenzo Guidi, Renato Maria Marsicano, Chrysanthi Koukoutzeli, Dario Trapani, Giuseppe Curigliano","doi":"10.1177/17588359241309461","DOIUrl":"https://doi.org/10.1177/17588359241309461","url":null,"abstract":"<p><p>Antibody-drug conjugates (ADCs) have emerged as a transformative approach in cancer therapy by enhancing tumor targeting and minimizing systemic toxicity compared to traditional chemotherapy. Initially developed with chemotherapy agents as payloads, ADCs have now incorporated alternative payloads, such as immune-stimulating agents, natural toxins, and radionuclides, to improve therapeutic efficacy and specificity. A significant advancement in ADC technology is the integration of Proteolysis Targeting Chimeras (PROTACs), which enable the precise degradation of cellular targets involved in tumorigenesis. This strategy enhances the specificity and precision of cancer therapies, addressing key mechanisms in cancer cell survival. Moreover, incorporating radioactive isotopes into ADCs is an emerging strategy aimed at further improving therapeutic outcomes. By delivering localized radiation, this approach offers the potential to enhance the efficacy of treatment and expand the therapeutic arsenal. Despite these innovations, challenges remain, including dysregulated immune activation, severe adverse effects, and intrinsic immunogenicity of some agents. These emerging issues highlight the ongoing need for optimization in ADC therapy. This review summarizes the latest developments in ADC technology, focusing on novel payloads, PROTAC integration, and the potential for combining ADCs with other therapeutic modalities to refine cancer treatment and improve patient outcomes.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241309461"},"PeriodicalIF":4.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selpercatinib in Chinese patients with <i>RET</i>-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial.","authors":"Shun Lu, Ying Cheng, Dingzhi Huang, Yuping Sun, Lin Wu, Chengzhi Zhou, Jianying Zhou, Ye Guo, Jingxin Shao, Wanli Zhang","doi":"10.1177/17588359241307199","DOIUrl":"10.1177/17588359241307199","url":null,"abstract":"<p><strong>Background: </strong>Selpercatinib is approved for the treatment of <i>RET</i>-fusion-positive non-small-cell lung cancer (NSCLC).</p><p><strong>Objective: </strong>We present a final update on LIBRETTO-321 to enhance the understanding of long-term efficacy and safety in Chinese patients.</p><p><strong>Design: </strong>This open-label, multicenter, phase II study included patients with advanced <i>RET</i>-altered solid tumors.</p><p><strong>Methods: </strong>The primary endpoint was objective response rate (ORR), and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was assessed by the independent review committee. Secondary endpoints were duration of response (DOR), progression-free survival (PFS), overall survival (OS), central nervous system (CNS) response, and safety.</p><p><strong>Results: </strong>A total of 47 patients (treatment-naïve (<i>n</i> = 11); pre-treated (<i>n</i> = 36)) with NSCLC were enrolled. The ORR in overall NSCLC was 72.3% (95% CI: 57.4, 84.4), treatment-naïve was 100.0% (95% CI: 71.5, 100.0); and pre-treated was 63.9% (95% CI: 46.2, 79.2). Median DOR was not reached for overall NSCLC, with 53% of responses ongoing at the data cutoff (median follow-up: 34.2 months). With a median follow-up of 35.9 months, the median PFS for overall NSCLC was 27.6 months (95% CI: 22.3, not evaluable (NE)), treatment-naïve was 27.6 months (95% CI: 16.4, NE), and pre-treated was 27.8 months (95% CI: 19.29, NE). The 3-year OS rate for overall NSCLC was 62.0% (95% CI: 45.9, 74.6) with a median follow-up of 38.1 months. Among five patients with measurable CNS metastases, four achieved intracranial responses. The safety profile was consistent with previous reports.</p><p><strong>Conclusion: </strong>With additional follow-up, selpercatinib showed durable responses, prolonged survival, and a consistent safety profile in Chinese patients with <i>RET</i>-fusion-positive NSCLC.</p><p><strong>Trial registration: </strong>Clinical Trials.gov identifier (NCT04280081).</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241307199"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical resection versus thermal ablation: comparison of sequential options after successful TACE downstaging therapy for unresectable hepatocellular carcinoma.","authors":"Chao An, Songsong Wu, Mengxuan Zuo, Wang Li, Kai Li, Peihong Wu","doi":"10.1177/17588359241306648","DOIUrl":"https://doi.org/10.1177/17588359241306648","url":null,"abstract":"<p><strong>Background: </strong>Transarterial chemoembolization (TACE) is an effective and safe downstaging therapy for hepatocellular carcinoma (HCC). However, the selection of sequential therapeutic modalities is still controversial.</p><p><strong>Objectives: </strong>This study compared the effectiveness and safety of surgical resection (SR) and thermal ablation (TA) after patients with HCC underwent TACE downstaging therapy.</p><p><strong>Design: </strong>A retrospective, multi-institutional study.</p><p><strong>Methods: </strong>From June 2008 to October 2022, a total of 4782 consecutive patients with HCC beyond the initial Milan criteria underwent TACE at 12 hospitals. Among them, 609 patients who received successful downstaging therapy were retrospectively reviewed. Among them, 209 patients underwent an SR, and 390 patients received TA after TACE. The propensity score matching (PSM) method was applied to reduce selection bias between groups. Cumulative overall survival (OS) and progression-free survival (PFS) were compared using the Kaplan-Meier method with the log-rank test.</p><p><strong>Results: </strong>After PSM 1:1 (<i>n</i> = 185 in both groups), the cumulative 1-, 3-, 5-, and 10-year OS rates were 98.8%, 89.3%, 82.9%, and 64.4%, respectively, in the SR group and 99.5%, 88.4%, 75.3%, and 53.9%, respectively, in the TA group; these two groups were not significantly different (HR: 1.22; 95% CI: 0.78-1.89; <i>p</i> = 0.381). The cumulative 1-, 3-, 5-, and 10-year PFS rates were 88.5%, 69.2%, 58.8%, and 32.2%, respectively, in the SR group and 90.6%, 71.4%, 53.1%, and 32.0%, respectively, in the TA group, revealing no significant difference between the two groups (HR: 0.97; 95% CI: 0.71-1.32; <i>p</i> = 0.855).</p><p><strong>Conclusion: </strong>For HCC patients beyond the Milan criteria who received TACE downstaging therapy, TA might be acceptable as an alternative to SR in the first-line sequential treatment scheme.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241306648"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial.","authors":"Ming Gao, Xia Zhang, Huan Yan, Yan Zhao, Fang Yuan, Decong Sun, Xuejiao Yang, Yanfang Ju, Lijie Wang, Haitao Tao, Luyuan Tian, Changhong Zhao, Junxun Ma, Yi Hu, Zhefeng Liu","doi":"10.1177/17588359241311058","DOIUrl":"https://doi.org/10.1177/17588359241311058","url":null,"abstract":"<p><strong>Background: </strong>For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) mutations.</p><p><strong>Objectives: </strong>This study aimed to evaluate the efficacy and safety of camrelizumab plus famitinib in previously treated patients with locally advanced and metastatic NSCLC.</p><p><strong>Design: </strong>A single-center, single-arm, phase II study.</p><p><strong>Methods: </strong>Previously treated patients with locally advanced and metastatic NSCLC were enrolled to receive camrelizumab (200 mg, administered intravenously every 3 weeks) and famitinib (20 mg, administered orally once daily). Patients harboring EGFR mutation genes had received at least one EGFR tyrosine kinase inhibitor and no more than two lines of chemotherapy regimen before the enrollment. The other patients had progressed on first-line chemotherapy with or without immunotherapy before the enrollment. The primary endpoint was the objective response rate (ORR) per RECIST v1.1 by the investigator.</p><p><strong>Results: </strong>Our study encompassed 23 NSCLC patients between October 2019 and October 2022. For all patients, the confirmed ORR was 30.4%, and the disease control rate was 95.7%. The median progression-free survival (PFS) was 6.9 months (95% CI: 4.9 months-not reached). The median overall survival (OS) was not reached. 1- and 2-year OS rates were 85.6% (95% CI: 71.8%-100.0%) and 56.8% (95% CI: 37.7%-85.7%). Especially, for the 6 patients with EGFR genetic aberrations, the confirmed ORR was 33.3%, the median PFS was 10.3 months (95% CI: 1.8-18.8 months), and the median OS was 20.3 months (95% CI: 0.8-39.8 months). The most common grade 3 and above treatment-related adverse events were platelet count decreased, white blood cell count decreased, and hypertension. No unexpected adverse events were reported.</p><p><strong>Conclusion: </strong>Camrelizumab plus famitinib demonstrated encouraging clinical activity with a manageable safety profile in previously treated patients with locally advanced and metastatic NSCLC. The results warranted further validation.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry identifier: ChiCTR1900026641.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241311058"},"PeriodicalIF":4.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.","authors":"Nadia Ghazali, Jamie Feng, Katrina Hueniken, Khaleeq Khan, Karmugi Balaratnam, Thomas K Waddell, Kazuhiro Yasufuku, Andrew Pierre, Laura Donahoe, Elliot Wakeam, Marcelo Cypel, Jonathan Yeung, Shaf Keshavjee, Marc de Perrot, Natasha B Leighl, Geoffrey Liu, Penelope A Bradbury, Adrian Sacher, Lawson Eng, Tracy Stockley, Ming Sound Tsao, Frances A Shepherd","doi":"10.1177/17588359241308466","DOIUrl":"10.1177/17588359241308466","url":null,"abstract":"<p><strong>Background: </strong>Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCLC. Exploring baseline outcomes for early-stage NSCLC with these rare mutations is crucial.</p><p><strong>Objectives: </strong>This study aims to assess relapse-free survival (RFS) and overall survival (OS) in patients with resected early-stage NSCLC with rare targetable driver mutations.</p><p><strong>Methods: </strong>This retrospective single-center study identified stage I-III NSCLC patients with rare targetable mutations who underwent curative surgery. Tissue-based molecular profiling identified mutations in <i>KRAS</i>G12C, <i>EGFR</i> Exon20, Erb-B2 receptor tyrosine kinase 2 (<i>ERBB2</i>), <i>ALK</i>, <i>ROS1</i>, B-Raf proto-oncogene (<i>BRAF</i>) V600E, mesenchymal-epithelial transition factor (<i>MET</i>) exon14 skipping, and rearranged during transfection (<i>RET</i>). Baseline patient and tumor characteristics, mutation subtype, and <i>TP53</i> co-mutation were correlated with RFS and OS using Cox regression. The <i>KRAS</i>G12C cohort was used as the reference for survival comparisons.</p><p><strong>Results: </strong>Among 225 patients, mutations included the following: <i>KRAS</i>G12C (<i>n</i> = 101, 45%), <i>MET</i> exon 14 skipping (<i>n</i> = 26, 12%), <i>EGFR</i> Exon 20 (<i>n</i> = 25, 11%), <i>ERBB2</i> (<i>n</i> = 25, 11%), <i>ALK</i> fusion (<i>n</i> = 16, 7%), <i>ROS1</i> fusion (<i>n</i> = 14, 6%), <i>BRAF</i> V600E mutation (<i>n</i> = 13, 6%), and <i>RET</i> fusion (<i>n</i> = 5, 2%). Five-year survival probabilities were 76% for stage I, 60% for stage II, and 58% for stage III. RFS was shorter across most mutation subgroups compared to <i>KRAS</i>G12C, with <i>ROS1</i> mutations showing significantly poorer RFS (HR 2.70, <i>p</i> = 0.019). By contrast, all mutation subgroups were associated with better OS than <i>KRAS</i>G12C. The incidence of brain metastasis was highest in <i>ERBB2</i> (22% at 5 years). TP53 co-mutation was associated with significantly worse OS (HR 2.35, <i>p</i> = 0.008).</p><p><strong>Conclusion: </strong>While RFS was poorer for most mutations compared to <i>KRAS</i>G12C, OS generally was better, suggesting a potential role for postoperative targeted therapies. These findings warrant further investigation through prospective studies and clinical trials to optimize adjuvant treatment strategies for patients with early-stage NSCLC harboring rare driver mutations.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241308466"},"PeriodicalIF":4.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer.","authors":"Kexin Ye, Chaohui Yu, Zhe Shen","doi":"10.1177/17588359241309825","DOIUrl":"10.1177/17588359241309825","url":null,"abstract":"<p><p>Chimeric antigen receptor T (CAR T) cells have shown their potential in hematological malignancies and the treatment of solid tumors, especially in metastases. However, CAR T-cell therapy may carry risks of inducing severe adverse effects, which are recognized as immune-related adverse events. Here, we report two cases of severe colitis presented with refractory bloody diarrhea, which were induced by carcinoembryonic antigen (CEA)-directed CAR T therapy in the treatment of metastatic colorectal adenocarcinoma. These patients were treated as part of a clinical trial. The clinical trial was registered at ClinicalTrials.gov (NCT05396300), submitted, and started on May 25, 2022. Glucocorticoids combined with vedolizumab were used to control their gastrointestinal symptoms but the outcomes were unsatisfactory. This report highlights the potentially serious risks of anti-CEA CAR T therapy and provides management options.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241309825"},"PeriodicalIF":4.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness, pharmacokinetics, and safety of triptorelin acetate microspheres in patients with locally advanced and metastatic prostate cancer.","authors":"Guolan Wu, Feng Zhou, Haiping Wang, Kan Liu, Dexin Yu, Lianlian Fan, Yangyun Han, Xiaohong Ai, Youhan Cao, Xiaolin Wang, Sheng Wang, Chaohong He, Jitao Wu, Ji Wu, Youlei Wang, Yanqing Wang, Baiye Jin, Jianzhong Shentu","doi":"10.1177/17588359241307818","DOIUrl":"10.1177/17588359241307818","url":null,"abstract":"<p><strong>Background: </strong>A newly generic microspheres, sustained-release formulation of triptorelin acetate 3.75 mg has been developed.</p><p><strong>Objectives: </strong>To evaluate the efficacy, pharmacokinetics, and safety of triptorelin 1-month formulation in Chinese patients with prostate cancer.</p><p><strong>Design: </strong>An open-label, multicenter clinical trial with one arm testing a 1-month sustained-release triptorelin formulation in prostate cancer patients.</p><p><strong>Methods: </strong>Patients with prostate cancer received three consecutive 28-day injections of triptorelin acetate. The primary endpoint was the proportion of successful patients over the total number of evaluable patients. Treatment success was defined as testosterone suppression below the clinical castration level (i.e., <0.5 ng/mL) at day 28 and maintenance of clinical castration until study completion (day 84). The frequency of patients with testosterone concentrations <0.2 ng/mL was also studied.</p><p><strong>Results: </strong>The study included 125 patients. All 125 patients received at least one dose of the study drug and 122 completed the study. The successful patient proportion among the evaluable patients was 97.6% (122/125; 95% CI, 92.7-99.2). 95.1% (116/122) achieved testosterone concentrations <0.2 ng/mL. The pharmacokinetic profile of triptorelin during the first 3 months of treatment, evaluated in a subset of the study population (<i>n</i> = 11), showed sustained release of triptorelin from the formulation. Values for AUC_0-τ calculated from day 0 to 28, and day 56 to 84 were 134.42 (28.76), and 154.72 (21.86) h*ng/mL, respectively. The most common treatment-related adverse events were increased alanine aminotransferase (18.4%), increased aspartate aminotransferase (16.0%), and hot flashes (9.6%). Prolonged QT interval on electrocardiogram, erectile dysfunction, and decreased libido each occurred in ⩽4% of the patients. The frequently reported local adverse reaction was pain at the injection site, experienced by 2.4% (3/125) of the patients.</p><p><strong>Conclusion: </strong>3.75-mg Triptorelin acetate microspheres for injection were effective in achieving and maintaining testosterone suppression and were well tolerated in patients with prostate cancer.</p><p><strong>Trial registration: </strong>chictr.org.cn (ChiCTR2000033188).</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241307818"},"PeriodicalIF":4.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.","authors":"Isabel Miras, Ana Gil, Marta Benavent, María Ángeles Castilla, Begoña Vieites, María Ángeles Dominguez-Cejudo, Sonia Molina-Pinelo, Lina Alfaro, Javier Frutos, Manuel Ruiz-Borrego, Alejandro Falcón, Mónica Cejuela, Javier Salvador-Bofill","doi":"10.1177/17588359241309169","DOIUrl":"10.1177/17588359241309169","url":null,"abstract":"<p><strong>Background: </strong>Complete pathological response to neoadjuvant treatment (NAT) in breast cancer is associated with prolonged survival. Compared to other breast cancer immunophenotypes, luminal tumors are the least chemosensitive with low rates of pathological response within this molecular subtype. Thus, finding predictors of response in this subset remains challenging. The emerging concept of low human epidermal growth factor receptor 2 (HER2) expression has led to a repurpose of the current prognostic system. Little is known about its correlation with response to NAT.</p><p><strong>Objectives: </strong>This study aims to evaluate predictors of response in early-stage luminal breast cancer receiving neoadjuvant chemotherapy.</p><p><strong>Design: </strong>A total of 252 luminal patients who received NAT were retrospectively assessed in this cohort study.</p><p><strong>Methods: </strong>We analyzed the correlation of ki67 and HER2 low expression with the rate of pathologic response. Using ki67 as a continuous variable and applying the receiver operating characteristic curves method.</p><p><strong>Results: </strong>We identified that in patients with a ki67 expression level >37%, the probability of having a complete pathological response was 4.80 times higher (odds ratio = 4.80, 95% confidence interval: 1.92-12.04). In Her2-low breast cancer patients, Her2 expression did not correlate with a better response rate.</p><p><strong>Conclusion: </strong>In our study, a ki67 expression value greater than 37% constitutes a predictive biomarker of pathological complete response in the subgroup of patients with luminal B tumors and could be considered, therefore, an indicator for treatment decisions in this subgroup.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241309169"},"PeriodicalIF":4.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter retrospective study of the combination of immune checkpoint inhibitors and chemotherapy regimens with or without liver metastasis for the first-line treatment of advanced gastric cancer.","authors":"Jing Ren, Ke Wang, Qianhao Meng, Chang Xu, Changqing Liu, Yusheng Wang, Guangyu Wang","doi":"10.1177/17588359241308389","DOIUrl":"10.1177/17588359241308389","url":null,"abstract":"<p><strong>Background: </strong>Several studies have indicated that the use of immune checkpoint inhibitors (ICI) can prolong the survival of patients with advanced gastric cancer (AGC). However, it remains unclear whether the presence of liver metastasis leads to systemic immune suppression, resulting in poorer immune therapy outcomes. This study aims to investigate whether liver metastasis affects the efficacy of ICI in first-line treatment for AGC patients.</p><p><strong>Methods: </strong>The data of AGC patients undergoing combined immunotherapy and chemotherapy treatment at Harbin Medical University Cancer Hospital and the First Hospital of Shanxi Medical University from January 2018 to January 2023 were collected. The Kaplan-Meier method and Cox proportional hazards regression analysis were employed to analyze the overall survival (OS) and progression-free survival (PFS) of the patients.</p><p><strong>Results: </strong>A total of 162 patients with AGC who were human epidermal growth factor receptor 2 (Her 2) negative and treated with immunotherapy in the first line were included in the study. Patients were divided into two groups, the liver metastasis group (LM group, <i>n</i> = 40) and the group without liver metastasis (NLM group, <i>n</i> = 122) according to the presence of liver metastasis. The results of the present study indicate that there was no statistically significant difference in the median OS, with median OS of 17 and 15 months, respectively (<i>p</i> = 0.29). Similarly, no significant difference was observed in the median PFS between the two groups (<i>p</i> = 0.65).</p><p><strong>Conclusion: </strong>This study suggests that the presence or absence of liver metastasis does not significantly affect the prognosis of AGC patients receiving first-line treatment with ICI.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241308389"},"PeriodicalIF":4.3,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}